Zomedica Corp. (ZOMDF)
OTCMKTS · Delayed Price · Currency is USD
0.0950
-0.0030 (-3.06%)
May 5, 2026, 3:52 PM EST
Zomedica Revenue
In the year 2025, Zomedica had annual revenue of $32.03M with 17.39% growth. Zomedica had revenue of $10.47M in the quarter ending December 31, 2025, with 32.63% growth.
Revenue
32.03M
Revenue Growth
+17.39%
P/S Ratio
3.00
Revenue / Employee
227.16K
Employees
141
Market Cap
96.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.03M | 4.75M | 17.39% |
| Dec 31, 2024 | 27.29M | 2.10M | 8.33% |
| Dec 31, 2023 | 25.19M | 6.26M | 33.05% |
| Dec 31, 2022 | 18.93M | 14.80M | 358.02% |
| Dec 31, 2021 | 4.13M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Allurion Technologies | 15.23M |
| QHSLab | 2.69M |
| Tian'an Technology Group | 2.12M |
| BioElectronics | 1.61M |
| PetVivo Holdings | 1.11M |
| Guided Therapeutics | 767.00K |
| Positron | 461.45K |
| Family Office of America | 221.77K |
Zomedica News
- 19 days ago - Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale - Accesswire
- 6 weeks ago - Zomedica Announces Strategic Collaboration with Boehringer Ingelheim to Expand Equine Endocrine Diagnostic Testing Using TRUFORMA(R) Platform - Accesswire
- 7 weeks ago - Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity - Accesswire
- 2 months ago - Zomedica to Review 2025 Financial Results and Highlight Equine Market Opportunity During March 27th "Fourth Friday at Four" Investor Webinar - Accesswire
- 2 months ago - Zomedica Transcript: Status update - Transcripts
- 2 months ago - Zomedica Expands Distribution of TRUVIEW(R) Digital Microscopy Platform Through National Agreement with Moichor, a Leader in Veterinary Pathology - Accesswire
- 3 months ago - Zomedica Announces "Fourth Friday at Four" Webinar on February 27th Focused on Research & Development and Its Innovation Pipeline - Accesswire
- 3 months ago - Zomedica Expands its TRUVIEW(R) Microscopy Platform with AI Diagnostic Interpretation, Growing its Market Opportunity - Accesswire